Notably, the incorporation of a CD39 inhibitor into a treatment regimen that combines a CD20 inhibitor and a CD47 inhibitor results in a significant enhancement of survival in a model of disseminated aggressive B-cell lymphoma [323]. Here, ENTPD1 is linked to B-cell non-Hodgkin lymphoma.